In June 2024, the sNDA for TUOYI ® in combination with paclitaxel for injection (albumin-bound) for the first-line treatment ...

If the past four decades have taught us anything about HIV, it's to adjust our expectations—despite enormous progress in controlling the virus, no treatment can yet completely eradicate HIV once it ...

Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., have described a next-generation vaccination technology ...

The modern cultivated strawberry (Fragaria x ananassa) originates from interspecific hybridization between two octoploid wild ...

Genomics encompasses the study of a complete set of genes, their work process, and their way of interacting with each other and the environment. While it incorporates elements of genetics, the primary ...

Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...

As per the scheme's terms, the merger will take effect from the first business day of the month following the fulfilment of ...

Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, infectious diseases, and fibrosis, today announced that the China National ...

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...

Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience ...